On 3 February 2023, the US Department of Justice announced the withdrawal of three antitrust policy statements that allowed certain information exchanges between competitors in healthcare markets. The day before this announcement, Principal Deputy Assistant Attorney General Doha Mekki of DOJ Antitrust Division warned that DOJ would reconsider these outdated policy statements in light of recent changes in the healthcare industry.
Baker McKenzie’s Sanctions Blog published the alert titled FinCEN Issues Alert on Potential Russia Sanctions Evasion in the US Commercial Real Estate Sector on 7 February 2023. Read the article via the link here. Please also visit our Sanctions Blog for the most recent updates.
In brief Finalized regulations under the amended California Consumer Privacy Act (“CCPA”) are one step closer to becoming…
Legislative activity in the US state of Washington continues this year with numerous bills being considered. Businesses that process health data should follow the process of House bill 1155 (the My Health, My Data Act), which has been amended once and was approved in the House Committee on Civil Rights & Judiciary hearing on 3 February 2023.
Through The Employer Report blog, our lawyers provide legal updates and practical insights to help clients understand, prepare for and respond to the latest domestic and cross-border Labor and Employment issues affecting US and multinational employers.
Through the Canadian Labour and Employment Law blog, our lawyers provide legal updates and practical insights to help clients understand, prepare for and respond to the latest domestic and cross-border Labour and Employment issues affecting Canadian and multinational employers.
Baker McKenzie’s Sanctions Blog published the alert titled Canada Sanctions Additional Russian Propagandists: 38 Individuals and 16 Entities Targeted on 6 February 2023. Read the article via the link here. Please also visit our Sanctions Blog for the most recent updates.
The Canada Border Services Agency announced anticipated annual updates to the Customs Tariff and its trade verification priorities. It has also announced the implementation date for CARM Release 2 and typical administrative and statutory trade remedy proceedings. In addition to these developments, it is possible that in 2023, Canada may implement its proposed amendments to the Valuation for Duty Regulations, continue to scrutinize the apparel industry, and apply enhanced scrutiny of imports and exports to determine whether goods were manufactured by forced or child labor or are at high risk for sanctions circumvention.
The US Food and Drug Administration ensures the quality of drug products by carefully monitoring both domestic and foreign drug manufacturers’ compliance with its Current Good Manufacturing Practice regulations. With over 350 manufacturing establishments supplying the US drug market, China represents one of the two countries with the most foreign drug establishments subject to FDA inspection.
The US Food and Drug Administration ensures the quality of drug products by carefully monitoring both domestic and foreign drug manufacturers’ compliance with its Current Good Manufacturing Practice regulations. With over 350 manufacturing establishments supplying the US drug market, China represents one of the two countries with the most foreign drug establishments subject to FDA inspection.